You are here: Industry Insights > Samsung

News List

Samsung commits billions of dollars to building its biologics business fiercepharma
August 09, 2018
Samsung has already spent billions of dollars in short order to establish one of the largest biologics manufacturing operations in the world. Today it said it will spend billions more.
Biogen to spend $700M to build its stake to 49.9% in biosims joint venture with Samsung fiercepharma
July 02, 2018
After Biogen reported first-quarter results back in April, CFO Jeff Cappello said the company would get further involved in an "attractive value creation" opportunity: its biosimiliars joint venture with Samsung BioLogics. Now, the drugmaker is disclosing
Samsung BioLogics granted FDA approval for its first monoclonal antibody Drug Substance pharmaasia
October 24, 2017
The Samsung Biologics plant is the largest single plant in the world, and this licensing allows it to manufacture Biologics Drug Substances commercially.
Samsung jumps into novel drug R&D through Takeda deal fiercebiotech
August 22, 2017
Samsung Bioepis has begun its long-anticipated move into novel drug R&D. The offshoot of South Korean conglomerate Samsung is taking its first steps beyond the lower risk, lower reward world of biosimilars by teaming up with Takeda to co-develop drugs aga
Samsung Bioepis joins hands with Takeda for biotech drugs biospectrumasia
August 22, 2017
The partnership will develop novel biologic drugs in "unmet disease areas".
Merck & Co., Samsung Bioepis introduce Remicade biosimilar Renflexis in US firstwordpharma
July 25, 2017
Merck & Co. and Samsung Bioepis on Monday announced the US launch of Renflexis (infliximab-abda).
Samsung Bioepis biosimilar wins tentative approval in US firstwordpharma
July 25, 2017
According to industry sources, Samsung Bioepis' biosimilar Lusduna Nexvue received tentative approval from the FDA, reported The Korea Herald.
Sun Pharma ties up with Samsung BioLogics financialexpress
July 05, 2017
Samsung BioLogics will manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis
Samsung BioLogics named best bio product firm in Asia biospectrumasia
April 28, 2017
The biosimilar product manufacturing affiliate of Samsung Group said it won the recognition at the Asia-Pacific Bioprocessing Excellence Awards 2017 in Singapore for achieving improvements in quality and manufacturing speed.
Samsung Bioepis receives FDA approval for Renflexis across all eligible indications pharmaceutical-technology
April 26, 2017
Samsung Bioepis has received the US Food and Drug Administration (FDA) approval for its biosimilar referencing...

Previous page 1 2 3 4 Next page